Overview

MAD Refractory: Solid Tumor QD w/o Break

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb